Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: A prospective study was performed to compare the efficacy and safety of intravesical mitomycin C (MMC) instillation for the prophylaxis of bladder cancer at different concentrations (30 mg or 40 mg). Materials and Methods: Ninety-seven patients that received complete transurethral resection for superficial bladder cancer were divided into two-randomized groups. One group (n=53) received 30 mg and the other group (n=44) received 40 mg dose of MMC weekly for 8 weeks, which was followed monthly for 10 months as maintenance therapy. The recurrence rates and side effects in both groups were recorded. The mean follow-up period was 32.4 months in the 30 mg group, and 32.0 months in the 40 mg group. Results: The overall one and two year recurrence rates were 19% and 24% in the 30 mg group, and 12% and 22% in the 40 mg group, which was not significantly different (p>0.05). Most of the side effects were mild and transient. Moreover, the rates of the individual side effects were not statistically different in the two groups. Conclusion: Our comparison of 30 mg and 40 mg intravesical MMC instillation showed no difference in either response or side effects. Thus, we tentatively conclude that we can use 30 mg instead of 40 mg as an intravesical MMC instillation dose.
Abstract
Purpose: A prospective study was performed to compare the efficacy and safety of intravesical mitomycin C (MMC) instillation for the prophylaxis of bladder cancer at different concentrations (30 mg or 40 mg). Materials and Methods: Ninety-seven patients that received complete transurethral resection for superficial bladder cancer were divided into two-randomized groups. One group (n=53) received 30 mg and the other group (n=44) received 40 mg dose of MMC weekly for 8 weeks, which was followed monthly for 10 months as maintenance therapy. The recurrence rates and side effects in both groups were recorded. The mean follow-up period was 32.4 months in the 30 mg group, and 32.0 months in the 40 mg group. Results: The overall one and two year recurrence rates were 19% and 24% in the 30 mg group, and 12% and 22% in the 40 mg group, which was not significantly different (p>0.05). Most of the side effects were mild and transient. Moreover, the rates of the individual side effects were not statistically different in the two groups. Conclusion: Our comparison of 30 mg and 40 mg intravesical MMC instillation showed no difference in either response or side effects. Thus, we tentatively conclude that we can use 30 mg instead of 40 mg as an intravesical MMC instillation dose.
참고문헌 (16)
- "an analysis of 315 cases", pp.250~2 (1982)
- "Prognostic indexes in patientstreated with intravesical bacillus calmette - guerin for super-ficial bladder cancer", 23, pp.835~42 (1991)
- "The plight of the patientwith carcinoma in situ of the bladder", 103, pp.160~4 (1970)
- "Long-term results of intravesical therapy for superficialbladder cancer", 19, pp.573~80 (1992)
- "Long-term mitomycinC instillation after transurethral resection of superficialbladder carcinoma Influence on recurrence", pp.27~9 (1984)
- "Mitomycin Cbladder instillation therapy for bladder tumors", 114, pp.217~9 (1975)
- "Effectiveness of a single immediate mitomycin C instillationin patients with low risk superficial bladder cancer:shortand long-term followup", 161, pp.1120~3 (1999)
- "Treatment of superficial bladdercancer with intravesical chemotherapy", 13, pp.335~41 (1997)
- "Intravesical bacillus Calmette-Guerin is superior to mitomycinC in reducing tumour recurrence in high-risk superficialbladder cancer:a meta-analysis of randomized trials", 93, pp.485~90 (2004)
- "A comparison of mitomycinC and bacillus calmette-guerin for the prophylaxis ofhigh risk superficial bladder tumors", 33, pp.1014~9 (1992)
- "A comparison of mitomycin C pasteur strainbcg and tice strain bcg for the prophylaxis of superficialbladder tumor", pp.945~50 (1997)
- "Prophylactic effect of mitomycinC and bacillus calmette-guerin in stage t1 of the superficialbladder cancer", 38, pp.957~62 (1997)
- "The use of intravesical thio-tepa in the management ofnon-invasive carcinoma of the bladder", 125, pp.307~12 (1981)
- "Intravesical chemotherapy with epirubicin:adose response study", 161, pp.1490~3 (1999)
- "The effect of intravesical mitomycin C on the recurrenceof superficial(Ta-T1) bladder cancer. A Hungarian MulticenterStudy.", 31, pp.451~6 (1999)
- "Complications of intravesicalchemotherapy", 19, pp.529~39 (1992)